Shares of VIVUS Inc (NASDAQ:VVUS) shot up 9.6% during mid-day trading on Tuesday after the company announced better than expected quarterly earnings, Analyst Ratings.Net reports. The company traded as high as $5.95 and last traded at $5.69, with a volume of 6,664,347 shares. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.25 moved to $5.95 on last trade day and at the end of the day closed at $5.57 Company price to sales ratio in past twelve months was calculated as 7.10 and price to cash ratio as 1.68. VIVUS, Inc. (NASDAQ:VVUS) showed a positive weekly performance of 10.08%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it will provide a corporate update and report first quarter 2014 financial results after the NASDAQ Global Select Market closes on Monday, May 12, 2014. That same day, Arena will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the “Arena Pharmaceuticals’ First Quarter 2014 Financial Results Call. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell -0.44% in last trading session and ended the day on $6.85. ARNA return on equity ratio is recorded as -19.10% and its return on assets is -6.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yearly performance is -8.91%.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has made a series of announcements pertaining to release of its 1Q2014 results along with shuffle in its key managerial positions. It is a pioneer in innovation and development of new technology and treatment of cancers including acute leukemia, lung cancer, etc. The company is a leading pioneer in the development of molecule drugs that help in deterring resistance in overcoming the fatal disease. Ariad pharmaceuticals have recently announced the release of new drug for the treatment of lung cancer. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -7.08 % in last trading session and was closed at $7.09 while trading in range of $7.08 – $7.61 – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is 3.96%.
Gilead Sciences Inc (NASDAQ:GILD) EVP Gregg Alton unloaded 13,000 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $79.08, for a total value of $1,028,040.00. Following the completion of the transaction, the executive vice president now directly owns 130,694 shares of the company’s stock, valued at approximately $10,335,282. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is 2.73%. On last trading day company shares ended up $78.32. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 3.94%. Analysts mean target price for the company is $99.50.
Leave a Reply